The peptide sequence contains an Aib residue at position 2, which occupies the DPP-4 binding site, conferring DPP-4 resistance
Common side effects include nausea, diarrhea, constipation, injection site reactions, and decreased appetite
Conclusion Remember to stay vigilant about your health while on semaglutide and report any concerning symptoms to your healthcare provider
Estimates of the background incidence of NAION in the general population range from approximately 7.73 to 11.35 per 100,000 person-years among individuals aged 40 and older, rising to 14.79 per 100,000 person-years in those aged 60 and above
J.Cras-MneurC.Bernal-MizrachiE
If you or a loved one is managing both type 2 diabetes and CKD, consult your doctor to learn more about this newly expanded treatment option